Articles On PainChek (ASX:PCK)

The latest quarterlies show that key drug and diagnostics developers are well funded for the task Cann Group enters company-saving debt and equity restructuring deal A rebirth for Monash IVF?      Today’s crop of quarterly reports shows t...

4DMedical (ASX:4DX) has popped once again on Wednesday after demonstrating its next-generation lung imaging tech at Stanford University, pushing the much-followed stock back closer to +300% gains. Listen to the HotCopper podcast for in-d...

ASX falls 73 points, sliding back below 9000 points Only three sectors marginally higher, XGD up 1.27pc Defence-related, energy and info tech stocks tumble   The ASX 200 couldn’t maintain much of its gains this week, giving up the fight j...

Experienced app marketing and growth specialist Sasha Grant appointed head of growth for PainChek Infant App Grant to lead scale-up and rollout of the app, which has regulatory clearance in Australia and Europe PainChek looks to replicate...

Aussie and Asian markets fall after Trump threatens more tariffs on China Gold and silver reach new record highs with strong demand for safe haven assets Materials sector slips into red in afternoon trade as tech leads laggards   The Auss...

The overall mood in the room in the final hour of the ASX on Monday is one of (somewhat bruised) relief – Trump’s latest tariff threats against China, which over the weekend led many investors to predict a second ‘April 2’ slaughter – haven...

Catapult Group is buying a German soccer analytics and talent scouting firm for $140 million PainChek signs its maiden US aged-care client Biotechs flock to the funding well – with more raisings to come   A global leader in athlete health...

Painchek (ASX:PCK) shares dipped red on Monday following the company’s news it’s inked a deal with Jewish Home Family, an aged care facility in New Jersey, as part of a US$26,000 (A$40,000) three-year contract offering exposure to its flags...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 41 of the year, I’m Jon Davidson. In this segment the top stocks most watched and most discussed by you, HotCopper users, let’s get straight into it starting with the most...

ASX down 9 points as AI jitters and profit taking set in Healthcare, materials sectors limit losses with some solid gains PainChek and Neurotech grab headlines with FDA wins; Dimerix also gains on strong news Glencore Mt Isa smelter bailed...

Highlights Tech, gold, and retail stocks weighed on the Australian market. James Hardie led gains with strong building materials demand. Pro Medicus expanded its European footprint with a major hospital contract. Austr...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

PainChek can now tackle the US$100 million US aged-care market – while other geographies beckon Trivarx shares leap 9% on depression detection trial results Dimerix gets more assurances on using surrogate endpoints in its pivotal kidney t...

Shares in junior healthcare technology company PainChek Ltd (ASX: PCK) have reached a 12-month high, up more than 30%, following the company's clearance of a key regulatory hurdle in the US. PainChek informed the ASX in a statement on W...

ASX slides 24.6 points with 10 of 11 sectors lower Materials sector squeaks into green on gold gains Resources stocks limit broad losses Gold miners do the hard yards The ASX 200 moved broadly lower today, down 0.27% on general market we...

Echo IQ has had a “frustrating” US reimbursement rejection, but there’s a Plan B Artrya signs up US hospital heart heavy hitter for its Sapphire trial Dorsavi gains traction in the US physical therapy sector   Heart disease detection play...

PainChek Limited (ASX:PCK), a company that ultimately produces an app best used for monitoring residents in aged care homes, has surged over +50% in the last week alone to 8cps; bringing YTD gains to +175%. The fairly sleepy microcap health...

The US Food and Drug Administration next week should clear PainChek’s pain detection app for the US aged-care sector Painchek made its FDA entreaty under the harder, more exclusive De Novo (new device) route The entreaty opens the way to a...

FDA classifies medical devices based on the type of device and the level of risk it poses Three main FDA clearances for medical devices are 510(k), de novo and pre-market approval  Several ASX companies have recently been granted FDA clear...

ASX 200 closes in red ahead of US Federal Reserve interest rate decision Energy sector jumps as Ukraine strikes on Russian oil refineries lift global oil prices DroneShield up 3% after announcing nearly $8 million in new contracts with the...

Painchek (ASX:PCK), a company once developing medical devices (read: apps) that allowed users with limitations to self-report pain, but which has since turned towards the aged care market, has seen support for its value prop in that latter...

Emvision secures $12 million in a placement, with up to $3 million to come in a share purchase plan Painchek’s Highland Fling reaps trial rewards Visionflex cleans up its balance sheet   Emvision Medical Devices (ASX:EMV) has replenished...

PainChek delivers strong clinical and economic benefits to aged care providers in Scottish care trial Evaluation confirms significant clinical benefits across a range of areas along with economic advantages PainChek also successfully comp...

  In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several compa...

PainChek App uses AI  to analyse facial muscle movements and detect pain in adults with unreliable communication skills FDA clearance forecast in October could make PainChek only US-approved pain assessment tool for dementia in aged care A...

Despite myriad pressures under the Trump regime, the FDA’s drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of...

Losses outweigh gains despite energy sector lift ASX has bled 1.03pc over last week Resource 200 index falls 1.1pc and All Ord Gold 2pc   Energy rally runs out of fuel Gains in the energy sector (+1.8%) just weren’t enough to offset a bru...

ASX falls 0.31pc with 10 of 11 sectors down Healthcare moves against the grain, up 1.04pc Fortescue jumps 4.34pc on quarterly results ASX looking poorly by end of trade The ASX 200 stumbled a little today, down 0.31% with 10 of 11 sector...

Medical device makers – including ASX-listed heart plays – are the likely winners from the US healthcare chaos Painchek hopes for US device approval by September Mayne Pharma flags legal action over Cosette bid but also waves an olive bra...

 Optiscan’s telepathology streaming software enables surgeons to have secure real-time access to pathologists – no matter where they are in the world 4D Medical’s device probes the lung’s innards without the nasties Painchek signs a US dis...

Smartphone pain assessment app developer PainChek (ASX: PCK) has signed a new reseller and integration agreement with Minneapolis-based assisted living provider Eldermark Software to help expand its US market reach. Under the terms of the 1...

Nanosonics scores FDA De Novo approval in March EMVision is also targeting De Novo for its brain scanner The company’s big potential in the US   When Nanosonics (ASX:NAN) landed FDA De Novo clearance for its CORIS system back in March, th...

The ASX200 closed up 0.58% at 8.343 points after the RBA cut rates by 25 basis points. IT was the best performing sector, up 2.3%, followed by Real Estate, up 1.4%, and Telecommunications, up 1.2%. Utilities was only substantial loser...

Painchek is awaiting US approval for its digital pain-assessment tool The US aged-care market is ten times bigger than Australia’s The company is also eyeing the much bigger infant market   PainChek (ASX:PCK) CEO Philip Daffas has a simpl...

PainChek Ltd (ASX:PCK) has raised $5.1 million through a capital raising initiative aiming to boost the market footprint of its adult pain assessment and monitoring application, in addition to ensuring completion of activities to enable the...

The ASX200 has been down 0.34% at 8,345 points, as the bourse pulls back from yesterday’s record highs. Gold continues to jump, with rising demand for haven assets following an escalation of tensions in Russia’s invasion of Ukraine. Bull...

Painchek is eyeing a market of 1.7 million US aged-care beds for its pain-detection device Genetic Signatures sizes up a $400 million US market The latest thrills and spills at life sciences AGMs   PainChek (ASX:PCK) lodged a US Food &amp...

PainChek (ASX:PCK) has applied for Food and Drug Administration (FDA) De Novo approval for its new PainChek Adult App. The application comes hot on the heels of completion of a US-based validation study. A green light from the FDA wou...

  Philip Daffas – CEO & Managing Director – PainChek Limited (ASX:PCK) is a digital health company that offers a mobile app for pain assessment, using AI to analyse facial expressions and other indicators in patients unable to communica...

ASX rises  following Wall Street’s lead Cettire drops 12pc after disappointing earnings update Retail house Premier Investments surge after potential Myer deal   The ASX rose by 0.34% on Tuesday following Wall Street’s lead. Consumer dis...

PainChek (ASX: PCK) has announced positive outcomes from a US clinical validation study that will allow the company to progress with a Food and Drug Administration (FDA) De Novo submission for its Adult smartphone app. The study recruited 1...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings. The company reported on Wednesday the FDA’s overall Clinical Evaluation Report (CER) drawing fr...

PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was given for the PainChek app, an AI platform designed to analyse facial expressions, voc...

  Peter Milios: I'm Peter Milios from the Finance Use Network, and today I'm talking with PainChek. PainChek, trading under the ASX Code PCK with a market capitalization of 45 million, is the developer of the world's first smart-based pain...

  To register for Friday's webinar click here. PainChek (ASX:PCK), developer of the world’s first smart based pain assessment and monitoring application, has announced it has established a reseller agreement with Nourish Care, a leading UK...

14 Mar 2024 - A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).

After a day of profit taking yesterday, the ASX200 is set to stablilise, with futures tipping a 0.2 per cent rise. US markets traded mostly flat, although the Nasdaq shed 0.4 per cent ahead of US inflation data due to land late tonight o...